United States

Ben Hirschler

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Dec 13 2017

Bumper crop of new drugs fails to lift big pharma R&D returns

LONDON It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.

Dec 13 2017

Did Sanofi, WHO ignore warning signals on dengue vaccine?

CHICAGO/LONDON When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease.

Dec 11 2017

'Ground-breaking' new drug gives hope in Huntington's disease

LONDON Scientists have for the first time fixed a protein defect that causes Huntington's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.

Dec 11 2017

GSK's new pharma head on lookout for cancer deals to boost pipeline

LONDON GlaxoSmithKline will scout for deal opportunities in cancer medicine, as well as immunology, as the drugmaker seeks to rebuild its presence in oncology, its new head of pharmaceuticals told Reuters.

Dec 07 2017

More than 2,000 drugs now in cancer immunotherapy race

LONDON The race to develop new immunotherapy treatments against cancer has sparked an unprecedented explosion in the oncology drug pipeline, with more than 2,000 immune system-boosting agents now in development.

Dec 06 2017

Roche to seize leap-frog opportunity in lung cancer

LONDON After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer.

Dec 06 2017

GSK, other drugmakers bet on post-Brexit UK science

LONDON Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit.

Dec 05 2017

Rats join mosquitoes as targets for 'gene drive' pest control

LONDON Rodents have joined mosquitoes in the cross-hairs of scientists working on a next-generation genetic technology known as "gene drive" to control pests.

Dec 05 2017

Philippines halts sale of dengue vaccine as Sanofi downplays risk

MANILA/LONDON The Philippines has ordered French drugmaker Sanofi to stop the sale, distribution and marketing of its Dengvaxia dengue vaccine in the country after the company last week warned it could worsen the disease in some cases. | Video

Dec 04 2017

Poor regulation, dodgy pills spur plan for African drugs agency

LONDON Last July, Ugandan officials seized fake versions of the cancer drug Avastin on sale in Kampala, revealing only the tip of an iceberg of bogus medicines found all too often in Africa.


  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary